Clinical Trials
10 trialsNCT03394365 2026-05-22
ALLELE
Pierre Fabre Medicament
Phase 3 Recruiting
NCT04554914 2026-04-27
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Active not recruiting
NCT07075185 2026-04-24
inMMyCAR
Kelonia Therapeutics, Inc.
Phase 1 Recruiting
NCT03328078 2026-04-16
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Phase 1/2 Recruiting
NCT04329728 2026-04-15
OPAL
AVM Biotechnology Inc
Phase 1/2 Recruiting
NCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
NCT02952508 2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2 Active not recruiting
NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed
NCT02966756 2025-12-24
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AbbVie
Phase 2 Recruiting
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting